糖脂平治疗代谢综合征的临床研究

目的:评价糖脂平治疗痰瘀互阻型代谢综合征(MS)的临床疗效。方法:将符合标准的80例患者随机分为治疗组和对照组,在一般生活方式干预的基础上治疗组口服糖脂平颗粒(3 g,bid),对照组口服二甲双胍肠溶片(0.25 g,tid)治疗,疗程均为3个月,观察治疗前后两组空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)、收缩压(SBP)、舒张压(DBP)、空腹胰岛素(FINS)、稳态模型评估-胰岛素抵抗指数(HOMA-IR)、腰围(WC)、体重、体重指数(BMI)和中医证候的变化情况。结果:用药3月后,两组中医证候疗效比较,治疗组总有效率为86.84%,对照组为56.76%(P<0.05);治疗组能降低FPG,2 hPG,HbA1c,FINS,TC,TG,LDL-C,降低SBP,减轻体重,改善胰岛素抵抗(P<0.05),在调节血脂、降低血压、改善中医证候方面优于对照组(P<0.05)。结论:糖脂平可以有效调节痰瘀互阻型MS患者糖脂紊乱,是治疗MS安全有效的复方。

Treatment of Tangzhiping for Metabolic Syndrome

Objective: To evaluate clinical effect of Tangzhiping in treating patients of metabolic syndrome (MS) with phlegm and blood stasis syndrome. Method: Eighty cases of MS who met the research standards were randomly divided into the treatment group and the control group. Lifestyle interventions were given to both groups, Tangzhiping (3 g, bid) was used for the treatment group, and metformin tablets (0.25 g, tid) for the control group. The fasting blood glucose (FPG), 2 hours plasma glucose(2 hPG), glycosylated hemoglobin (HbA1c), total cholesterol (TC), low density lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C), triglyceride (TG), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting insulin (FINS), homeostasis model assessment of insulin resistance (HOMA-IR), weight, waist circumference (WC), body mass index (BMI) and clinical symptoms changes were compared between two groups after three months. Result: There months after treatment, the total efficiency on clinical syndrome in the treatments group was as high as 86.84%, higher than that of the control group of 56.76% (P<0.05). The treatment group could reduce FPG, 2 hPG, HbA1c,FINS, TC, TG, LDL-C, SBP and weight, and improve insulin resistance (P<0.05), especially in blood-lipid regulation, blood pressure decreased, clinical symptom improvement, the treatment group was significantly better than the control group (P<0.05). Conclusion: Tangzhiping can significantly regulate glucose-lipid disorder for MS patients with phlegm and blood stasis syndrome, and it is a safe and effective.